Stipple Bio
Precision oncology with epitope profiling
About
Founded in 2022, Stipple Bio is a biotechnology company developing precision oncology therapies using its proprietary Pointillist Platform, which identifies tumor-specific cell surface epitopes with high resolution. The company’s lead candidate, STP-100, is advancing into early clinical studies aimed at cancer treatment. Stipple Bio's business model centers on leveraging deep cellular profiling for discovery and development of high therapeutic index oncology assets. The company raised an oversubscribed $100M Series A financing in 2024 to fund operations into 2029, enabling expansion of its oncology pipeline beyond STP-100.
Products
- STP-100
- Pointillist Platform
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Stipple Bio — available to members.
Related Companies
Other startups in Biotech & Therapeutics
